|Bid||22.47 x 800|
|Ask||22.49 x 800|
|Day's Range||22.33 - 22.82|
|52 Week Range||12.71 - 25.96|
|Beta (3Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.19|
Biohaven Pharmaceutical slumped to a three-week low Wednesday after the biotech reported greater-than-expected third-quarter losses.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would stay away from Sociedad Quimica y Minera de Chile (NYSE: SQM ). He doesn't see any edge that could make him money in the stock. ...
Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017, which reflected ~18% YoY (year-over-year) growth. Xyrem’s net revenues over the first nine months of 2018 amounted to $1.0 billion—compared to $874.2 million in the same period in 2017, which reflects 18% YoY growth.
Warren Buffett is arguably the greatest investor of all time. Over his career, Buffett’s investing prowess formed one of the greatest conglomerates of all time and generated a lot of value for investors. In this article, examine four stocks that Buffett’s Berkshire Hathaway held in the second quarter and that company insiders have also bought in the last […]
Whenever a stock shoots higher, value investors justifiably hesitate on trading it. The stock priced in the good news already, leaving few extra gains ahead. So when Mylan N.V. (NASDAQ: MYL) rose by over 15% on the week, the best thing investors may do before buying Mylan stock is to look at the quarterly earnings result in detail.
Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.
Teva Pharmaceutical (NYSE:TEVA) is doing a lot better this year — up just shy of 20%. Its key drug, Copaxone, which treats multiple sclerosis, is facing generic competition from Mylan (NASDAQ:MYL), among others. The company has sold assets to clean up its balance sheet, which has de-risked the story somewhat.
In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~18% YoY (year-over-year) to $726.0 million from $882.0 million. It fell YoY to $2.3 billion in the first nine months of this year from $2.5 billion. The company’s international gross profit fell YoY to $301.0 million in the third quarter from $351.0 million, and to $942.0 million in the first nine months of this year from $1.0 billion.
In the third quarter, Teva Pharmaceutical’s (TEVA) European revenue fell ~12% YoY (year-over-year) to $1.2 billion from $1.38 billion. Its net European revenue fell YoY to $3.98 billion in the first nine months of this year from $4.02 billion.
In the third quarter, Teva Pharmaceutical’s (TEVA) North American Generic Medicines revenue fell ~25% YoY (year-over-year) to $922.0 million from $1.2 billion. In the first nine months of this year, it fell ~26% YoY to $3.0 billion from $4.0 billion.
Teva Pharmaceutical’s (TEVA) GAAP net income fell YoY (year-over-year) to -$273 million from $530.0 million in the third quarter, but rose YoY to $541.0 million from -$4.9 billion in the first nine months of this year. Teva’s GAAP diluted EPS fell YoY to -$0.27 from $0.52 in the third quarter, and to $0.53 from $4.85 in the first nine months of this year. The company’s non-GAAP net income and non-GAAP diluted EPS fell YoY to $694.0 million and $0.68, respectively, from $1.0 billion and $1 in the third quarter.
In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~19% YoY (year-over-year) to $4.5 billion. In the first nine months of this year, Teva’s net revenue fell ~16% YoY to $14.3 billion from $17.0 billion.
Both Bausch Health Cos. and Teva Pharmaceuticals have outperformed their peers and the market this year, but Morgan Stanley sees more gains ahead.
In October, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend approving Teva Pharmaceutical’s (TEVA) and Celltrion’s Biologics License Application for CT-P10, a proposed biosimilar to Roche’s (RHHBY) Rituxan. The recommended approval of CT-P10 was for three indications: as a monotherapy for relapsed or refractory B-cell non-Hodgkin’s lymphoma as a first-line treatment for B-cell NHL in combination with chemotherapy as a second-line monotherapy for non-progressing B-cell NHL after cyclophosphamide-, vincristine-, or prednisone-based chemotherapy
Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) last week reported a 19-percent drop in Q3 revenues, stung by generic competition to its multiple sclerosis drug Copaxone, price erosion at its U.S. ...
Healthcare has become the latest market to take full advantage of this trend. According to a paper by PwC called The Digital Healthcare Leap, the new trends are ripe for digital healthcare solutions in developed and emerging markets. As a result, the industry has expanded its focus to non-critical health care services to cater to this changing demand of present-day consumers.
Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.
NEW YORK, NY / ACCESSWIRE / November 2, 2018 / Teva shares were skyrocketing on a third quarter financial report that beat analysts’ estimates and a raised outlook. Shares of Sellas Life Sciences were ...
The generic drug giant reported third-quarter sales of $4.5 billion and adjusted earnings of 68 cents a share. While both figures were down significantly from a year earlier, the earnings figure topped expectations thanks to deeper cost cuts than analysts had anticipated. Teva also increased its full-year guidance for profit and free cash flow.